NO20013335L - Anvendelse av 4-H-1-benzopyran-4-on-derivater som inhibitorer av glatt muskelcelle proliferering - Google Patents
Anvendelse av 4-H-1-benzopyran-4-on-derivater som inhibitorer av glatt muskelcelle prolifereringInfo
- Publication number
- NO20013335L NO20013335L NO20013335A NO20013335A NO20013335L NO 20013335 L NO20013335 L NO 20013335L NO 20013335 A NO20013335 A NO 20013335A NO 20013335 A NO20013335 A NO 20013335A NO 20013335 L NO20013335 L NO 20013335L
- Authority
- NO
- Norway
- Prior art keywords
- benzopyran
- derivatives
- cell proliferation
- smooth muscle
- muscle cell
- Prior art date
Links
- 230000004663 cell proliferation Effects 0.000 title 1
- 150000004777 chromones Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24338099A | 1999-02-01 | 1999-02-01 | |
| US09/468,665 US6399633B1 (en) | 1999-02-01 | 1999-12-21 | Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| PCT/US2000/001104 WO2000044362A2 (en) | 1999-02-01 | 2000-01-18 | The use of 4-h-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20013335D0 NO20013335D0 (no) | 2001-07-05 |
| NO20013335L true NO20013335L (no) | 2001-09-25 |
| NO330512B1 NO330512B1 (no) | 2011-05-09 |
Family
ID=22918541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20013335A NO330512B1 (no) | 1999-02-01 | 2001-07-05 | Anvendelse av 4-H-1-benzopyran-4-on-derivater for fremstilling av et farmasoytisk preparat for inhibering av glatt muskelcelle proliferering |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6399633B1 (no) |
| EP (1) | EP1150746B1 (no) |
| JP (1) | JP4755759B2 (no) |
| KR (1) | KR100793047B1 (no) |
| CN (1) | CN1219556C (no) |
| AP (1) | AP1469A (no) |
| AR (1) | AR042569A1 (no) |
| AT (1) | ATE275428T1 (no) |
| AU (1) | AU777368B2 (no) |
| BG (1) | BG65151B1 (no) |
| BR (1) | BR0007911A (no) |
| CA (1) | CA2360668C (no) |
| CR (1) | CR6448A (no) |
| CZ (1) | CZ300395B6 (no) |
| DE (1) | DE60013555T2 (no) |
| DK (1) | DK1150746T3 (no) |
| EA (1) | EA004786B1 (no) |
| EE (1) | EE04851B1 (no) |
| ES (1) | ES2226792T3 (no) |
| HK (1) | HK1042445B (no) |
| HR (1) | HRP20010521A2 (no) |
| HU (1) | HU229263B1 (no) |
| ID (1) | ID30180A (no) |
| IL (1) | IL144668A (no) |
| ME (1) | MEP10508A (no) |
| NO (1) | NO330512B1 (no) |
| NZ (1) | NZ512822A (no) |
| OA (1) | OA11755A (no) |
| PL (1) | PL197693B1 (no) |
| PT (1) | PT1150746E (no) |
| RS (1) | RS50242B (no) |
| SI (1) | SI1150746T1 (no) |
| SK (1) | SK286747B6 (no) |
| TR (1) | TR200102223T2 (no) |
| TW (1) | TWI273907B (no) |
| UA (1) | UA73110C2 (no) |
| WO (1) | WO2000044362A2 (no) |
| ZA (1) | ZA200105596B (no) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0102480D0 (en) * | 2001-01-31 | 2001-03-14 | Cyclacel Ltd | Marker |
| PL211300B1 (pl) * | 2002-04-17 | 2012-05-31 | Cytokinetics Inc | Związek i kompozycja zawierająca ten związek |
| US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
| US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
| US20040082613A1 (en) * | 2002-06-28 | 2004-04-29 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| US20040106647A1 (en) * | 2002-06-28 | 2004-06-03 | Schneider Michael D. | Modulators of Cdk9 as a therapeutic target in cardiac hypertrophy |
| AU2003273299B2 (en) * | 2002-09-05 | 2010-04-01 | Medimmune, Llc | Methods of preventing or treating cell malignancies by administering CD2 antagonists |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| WO2004091510A2 (en) | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Recombinant il-9 antibodies and uses thereof |
| US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
| JP4934426B2 (ja) | 2003-08-18 | 2012-05-16 | メディミューン，エルエルシー | 抗体のヒト化 |
| EP2422811A2 (en) | 2004-10-27 | 2012-02-29 | MedImmune, LLC | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| EP1869192B1 (en) | 2005-03-18 | 2016-01-20 | MedImmune, LLC | Framework-shuffling of antibodies |
| US20070110757A1 (en) | 2005-06-23 | 2007-05-17 | Ziping Wei | Antibody formulations having optimized aggregation and fragmentation profiles |
| CA2617728A1 (en) * | 2005-07-15 | 2007-01-25 | Sahajanand Biotech Private Limited | Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis |
| JP2008255008A (ja) * | 2005-07-19 | 2008-10-23 | Tokyo Medical & Dental Univ | 滑膜細胞増殖抑制剤 |
| AU2006275514B2 (en) * | 2005-07-29 | 2012-04-05 | Resverlogix Corp. | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| US8058402B2 (en) | 2006-08-28 | 2011-11-15 | Kyowa Hakko Kirin | Antagonistic human LIGHT-specific human monoclonal antibodies |
| CA2676984C (en) | 2007-02-01 | 2015-03-17 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular diseases |
| US20110130544A1 (en) | 2007-03-30 | 2011-06-02 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
| US8114995B2 (en) | 2008-06-26 | 2012-02-14 | Resverlogix Corp. | Methods of preparing quinazolinone derivatives |
| ES2542835T3 (es) | 2009-01-08 | 2015-08-12 | Resverlogix Corporation | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
| JP5795304B2 (ja) | 2009-03-18 | 2015-10-14 | レスバーロジックス コーポレイション | 新規抗炎症剤 |
| KR101892987B1 (ko) | 2009-04-22 | 2018-08-30 | 리스버로직스 코퍼레이션 | 신규한 소염제 |
| US20130225530A1 (en) | 2010-07-12 | 2013-08-29 | Dkfz Deutsches Krebsforschungszentrum | Wogonin for the prevention and therapy of cardiac hypertrophy |
| DK2668210T3 (da) | 2011-01-26 | 2020-08-24 | Celldex Therapeutics Inc | Anti-kit antistoffer og anvendelser deraf |
| CA2851996C (en) | 2011-11-01 | 2020-01-07 | Resverlogix Corp. | Pharmaceutical compositions for substituted quinazolinones |
| SG11201500489YA (en) | 2012-07-25 | 2015-02-27 | Kolltan Pharmaceuticals Inc | Anti-kit antibodies and uses thereof |
| CA2887129A1 (en) | 2012-10-09 | 2014-04-17 | Igenica, Inc. | Anti-c16orf54 antibodies and methods of use thereof |
| WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
| WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
| EP2935253B1 (en) | 2012-12-21 | 2018-08-01 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| SG10201708143QA (en) | 2013-06-06 | 2017-11-29 | Pierre Fabre Médicament | Anti-c10orf54 antibodies and uses thereof |
| US9475874B2 (en) | 2013-08-26 | 2016-10-25 | MabVax Therapeutics, Inc. | Nucleic acids encoding human antibodies to sialyl-lewisa |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| KR102226248B1 (ko) | 2014-06-04 | 2021-03-12 | 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 | 강글리오사이드 ｇｄ２에 대한 사람 단클론 항체 |
| US10766959B2 (en) | 2014-12-11 | 2020-09-08 | Pierre Fabre Medicament | Anti-C10ORF54 antibodies and uses thereof |
| BR112017015880A2 (pt) | 2015-03-03 | 2018-07-31 | Kymab Ltd | anticorpos, usos e métodos |
| CA2977308A1 (en) | 2015-03-13 | 2016-09-22 | Resverlogix Corp. | Compositions and therapeutic methods for the treatment of complement-associated diseases |
| CN107995863A (zh) | 2015-04-20 | 2018-05-04 | 特雷罗药物股份有限公司 | 通过线粒体分析预测对阿伏西地的应答 |
| AU2016264212B2 (en) | 2015-05-18 | 2020-10-22 | Sumitomo Pharma Oncology, Inc. | Alvocidib prodrugs having increased bioavailability |
| WO2017024073A1 (en) | 2015-08-03 | 2017-02-09 | Tolero Pharmaceuticals, Inc. | Combination therapies for treatment of cancer |
| US11253590B2 (en) | 2015-12-02 | 2022-02-22 | Stsciences, Inc. | Antibodies specific to glycosylated BTLA (B- and T- lymphocyte attenuator) |
| WO2017096051A1 (en) | 2015-12-02 | 2017-06-08 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
| CN109803684B (zh) | 2016-08-23 | 2022-08-23 | 卫材 R&D 管理有限公司 | 用于治疗肝细胞癌的组合疗法 |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| SG11201908531WA (en) | 2017-03-16 | 2019-10-30 | Eisai R&D Man Co Ltd | Combination therapies for the treatment of breast cancer |
| EP3630834A1 (en) | 2017-05-31 | 2020-04-08 | STCube & Co., Inc. | Methods of treating cancer using antibodies and molecules that immunospecifically bind to btn1a1 |
| KR20200015602A (ko) | 2017-05-31 | 2020-02-12 | 주식회사 에스티큐브앤컴퍼니 | Btn1a1에 면역특이적으로 결합하는 항체 및 분자 및 이의 치료적 용도 |
| CN110997724A (zh) | 2017-06-06 | 2020-04-10 | 斯特库伯株式会社 | 使用结合btn1a1或btn1a1-配体的抗体和分子治疗癌症的方法 |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| US11707522B2 (en) | 2017-10-13 | 2023-07-25 | Boehringer Ingelheim International Gmbh | Human antibodies to Tn antigen |
| BR112021000934A2 (pt) | 2018-07-20 | 2021-04-27 | Pierre Fabre Medicament | receptor para vista |
| EP3890749A4 (en) | 2018-12-04 | 2022-08-03 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS CANCER TREATMENT AGENT |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| CN113559244B (zh) * | 2021-08-02 | 2023-12-26 | 华中科技大学同济医学院附属协和医院 | Ctrp13脂肪因子的新用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (no) * | 1986-04-11 | 1989-02-04 | Hoechst India | |
| US5284856A (en) * | 1988-10-28 | 1994-02-08 | Hoechst Aktiengesellschaft | Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives |
| US5733920A (en) | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
| US5849733A (en) | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
| US5908934A (en) | 1996-09-26 | 1999-06-01 | Bristol-Myers Squibb Company | Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs |
| JP2001509805A (ja) | 1997-02-05 | 2001-07-24 | ワーナー−ランバート・コンパニー | 細胞増殖阻害剤としてのピリド〔２，３−ｄ〕ピリミジンおよび４−アミノピリミジン |
-
1999
- 1999-12-21 US US09/468,665 patent/US6399633B1/en not_active Expired - Fee Related
-
2000
- 2000-01-18 AP APAP/P/2001/002218A patent/AP1469A/en active
- 2000-01-18 BR BR0007911-1A patent/BR0007911A/pt not_active Application Discontinuation
- 2000-01-18 ID IDW00200101696A patent/ID30180A/id unknown
- 2000-01-18 AU AU32098/00A patent/AU777368B2/en not_active Ceased
- 2000-01-18 DE DE60013555T patent/DE60013555T2/de not_active Expired - Lifetime
- 2000-01-18 CZ CZ20012804A patent/CZ300395B6/cs not_active IP Right Cessation
- 2000-01-18 OA OA1200100196A patent/OA11755A/en unknown
- 2000-01-18 KR KR1020017009716A patent/KR100793047B1/ko not_active IP Right Cessation
- 2000-01-18 TR TR2001/02223T patent/TR200102223T2/xx unknown
- 2000-01-18 CA CA002360668A patent/CA2360668C/en not_active Expired - Fee Related
- 2000-01-18 EE EEP200100385A patent/EE04851B1/xx not_active IP Right Cessation
- 2000-01-18 ES ES00909918T patent/ES2226792T3/es not_active Expired - Lifetime
- 2000-01-18 RS YU54401A patent/RS50242B/sr unknown
- 2000-01-18 EA EA200100742A patent/EA004786B1/ru not_active IP Right Cessation
- 2000-01-18 UA UA2001075481A patent/UA73110C2/uk unknown
- 2000-01-18 AT AT00909918T patent/ATE275428T1/de active
- 2000-01-18 SK SK1086-2001A patent/SK286747B6/sk not_active IP Right Cessation
- 2000-01-18 CN CNB008032513A patent/CN1219556C/zh not_active Expired - Fee Related
- 2000-01-18 DK DK00909918T patent/DK1150746T3/da active
- 2000-01-18 ME MEP-105/08A patent/MEP10508A/xx unknown
- 2000-01-18 SI SI200030517T patent/SI1150746T1/xx unknown
- 2000-01-18 JP JP2000595666A patent/JP4755759B2/ja not_active Expired - Fee Related
- 2000-01-18 PT PT00909918T patent/PT1150746E/pt unknown
- 2000-01-18 IL IL14466800A patent/IL144668A/xx not_active IP Right Cessation
- 2000-01-18 WO PCT/US2000/001104 patent/WO2000044362A2/en active IP Right Grant
- 2000-01-18 EP EP00909918A patent/EP1150746B1/en not_active Expired - Lifetime
- 2000-01-18 HU HU0200804A patent/HU229263B1/hu not_active IP Right Cessation
- 2000-01-18 NZ NZ512822A patent/NZ512822A/en not_active IP Right Cessation
- 2000-01-18 PL PL350735A patent/PL197693B1/pl not_active IP Right Cessation
- 2000-01-25 TW TW089101215A patent/TWI273907B/zh not_active IP Right Cessation
- 2000-02-01 AR ARP000100420A patent/AR042569A1/es not_active Application Discontinuation
-
2001
- 2001-07-05 NO NO20013335A patent/NO330512B1/no not_active IP Right Cessation
- 2001-07-06 ZA ZA200105596A patent/ZA200105596B/en unknown
- 2001-07-11 HR HR20010521A patent/HRP20010521A2/hr not_active Application Discontinuation
- 2001-07-27 BG BG105751A patent/BG65151B1/bg unknown
- 2001-08-23 CR CR6448A patent/CR6448A/es not_active Application Discontinuation
-
2002
- 2002-05-31 HK HK02104062.3A patent/HK1042445B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20013335L (no) | Anvendelse av 4-H-1-benzopyran-4-on-derivater som inhibitorer av glatt muskelcelle proliferering | |
| NO20021329D0 (no) | Kinaseinhibitorer som terapeutiske midler | |
| NO20014858D0 (no) | Anvendelse av CYP2D6 inhibitorer i kombinasjonsterapi | |
| NO20014409D0 (no) | Dimere forbindelser og deres anvendelse som inhibitorer av neuraminidase | |
| NO20021239L (no) | Pteridinoner som kinase-inhibitorer | |
| EE200300088A (et) | Imidasolo-5-üül-2-anilino-pürimidiinid raku proliferatsiooni inhibitsiooni agensitena | |
| DK1223933T3 (da) | 5-leddet derivater af heterocyklusser og deres anvendelse som monoaminoxidaseinhibitorer | |
| NO20015054L (no) | Legemidler omfattende inhibitorer av cellevolumregulert human Kinase H-SGK | |
| ATE260248T1 (de) | Zellproliferation inhibitoren | |
| NO20022125D0 (no) | Pyrrolderivater som inhibitorer for fosfodiesterase VII | |
| DK1226143T3 (da) | Imidazopyridinderivater som phosphodiesterase VII-inhibitorer | |
| DK1183251T3 (da) | Indolylpiperidinderivater som antihistamin- og antiallergimidler | |
| NO20016201D0 (no) | Tienopyrimidiner som fosfodiesteraseinhibitorer | |
| HUP0202401A2 (en) | Five-membered heterocyclic amidinec as prodrugs of thrombin inhibitors, pharmaceutical compositions comprising thereof and their use | |
| EE200100611A (et) | NOS inhibiitorite uued farmatseutilised kombinatsioonid | |
| NO20022123D0 (no) | Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII | |
| NO933699D0 (no) | Sulfaterte polysakkarider som hemmere av glatt muskelcelleproliferasjon | |
| NO20016403L (no) | Substituerte purinderivater som inhibitorer av celleadhesjon | |
| DK1222193T3 (da) | Imidazolderivater som phosphodiesterase VII-inhibitorer | |
| DK0830345T3 (da) | Styryl-benzimidazol-derivater som inhibitorer af glatmuskel-celleproliferation | |
| NO20015033L (no) | Anvendelse av maduraftalazinderivater som inhibitorer av proinflammatoriske cytokiner | |
| DZ3367A1 (fr) | Derives de 2-aminothiazoline et leur utilisation comme inhibiteurs de no-synthase | |
| NO20021965D0 (no) | Hydroksamsyrederivat som inhibitor av dannelsen av opplöselig, human CD23 | |
| AU4021700A (en) | Methods of use of beta1-integrin inhibitors | |
| NO20021249D0 (no) | Tienoisoksazolfenoksyusubstituerte etyl- og propylderivater som D4antagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |